CD4 and neoplasm: Later, it was confirmed that the drug inhibited tumor angiogenesis via upregulation of IFN-γ production by enhancing tumor infiltration of IFN-γ-expressing cells (CD4+, CD8+ T cells, NK cells, neutrophils and monocytes).